For the Inventor, By the Inventor

Enter assignee name

Guangdong, China

Sunshine Lake Pharma Co., Ltd.

USPTO Granted Patents = 119

CIPO Patents = 15

EPO Patents = 66

Forward Citations = 286

Loading Chart...

Loading Chart...

225 inventors (with patents filed for the assignee):

Yingjun Zhang (59 out of 62 patents)

Ning Xi (27 out of 76 patents)

Qingyun Ren (26 out of 27 patents)

4. Siegfried Goldmann (16 out of 100 patents)

5. Xinchang Liu (12 out of 12 patents)

6. Jiancun Zhang (12 out of 13 patents)

7. Chuanfei Jin (11 out of 11 patents)

8. Xiaojun Wang (11 out of 19 patents)

9. Zheng Gu (9 out of 10 patents)

10. Yanjun Wu (9 out of 9 patents)

11. Changhua Tang (8 out of 9 patents)

12. Junjun Yin (7 out of 8 patents)

13. Kai Yi (7 out of 8 patents)

14. Bing Liu (7 out of 9 patents)

15. Ji Zhang (7 out of 7 patents)

Core Competencies:

Teixobactin Analogue

Diarylamide Compound

Thienopyrimidine Derivatives

RET Inhibitors

Dual-Target Fusion Proteins

Vilazodone Inclusion Complexes

Influenza Virus Replication Inhibitors

Fused Tricyclic Compounds

Glucopyranosyl Derivatives

Dihydropyrimidine Compounds

Cathepsin K Inhibitors

Pyridinylmethylenepiperidine Derivatives

119 patents: Sort by Forward Citations

1. 12502387 - Lurasidone solid dispersion and preparation method thereof (2025-12-23),

2. 12492211 - Crystalline form of nitrogen-containing tricyclic compound and use thereof (2025-12-09),

3. 12435108 - Teixobactin analogue and use thereof (2025-10-07),

4. 12428432 - Thienopyrimidine derivatives having stereo configurations and use thereof in medicine (2025-09-30),

5. 12428389 - Diarylamide compound and application thereof (2025-09-30),

6. 12324812 - Glucopyranosyl derivatives and their uses (2025-06-10),

7. 12312348 - RET inhibitors, pharmaceutical compositions and uses thereof (2025-05-27),

8. 12258317 - Isoquinolinone compound for inhibiting ssao/vap-1, and use thereof (2025-03-25),

9. 12209085 - RET inhibitors, pharmaceutical compositions and uses thereof (2025-01-28),

10. 12171761 - Vilazodone inclusion complexes, compositions and preparation thereof (2024-12-24),

11. 12145974 - Dual-target fusion proteins comprising FGF21 and GLP-1, connected through a Fc portion of an immunoglobulin (2024-11-19),

12. 12128044 - Fused tricyclic compounds and uses thereof in medicine (2024-10-29),

13. 11858910 - Pyridinylmethylenepiperidine derivatives and uses thereof (2024-01-02),

14. 11679143 - FGF21 variant, fusion protein and application thereof (2023-06-20),

15. 11517569 - Vilazodone inclusion complexes, compositions and preparation thereof (2022-12-06),

Sunshine Lake Pharma is a leading pharmaceutical company that specializes in the research, development, and manufacturing of innovative and high-quality drugs. With a focus on improving global healthcare, Sunshine Lake Pharma has successfully launched numerous lifesaving medications across various therapeutic areas. Through continuous innovation and stringent quality control measures, Sunshine Lake Pharma ensures the safety and efficacy of its products. Our mission is to contribute to the well-being of society by providing affordable and accessible healthcare solutions to patients worldwide.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

119 Patents

#10 in Guangdong

#262 in China

#6,489 in the World

Guangdong, China

Sunshine Lake Pharma Co., Ltd.

Forward Citations = 286

225 inventors:

Yingjun Zhang (59 out of 62 patents)

Ning Xi (27 out of 76 patents)

Qingyun Ren (26 out of 27 patents)

4. Siegfried Goldmann (16 out of 100 patents)

5. Xinchang Liu (12 out of 12 patents)

Please report any incorrect information to support@idiyas.com

Loading…